Onconetix, Inc. Defined Benefit Plan, Expected Return (Loss) on Plan Assets
Onconetix, Inc. (ONCO) reported Defined Benefit Plan, Expected Return (Loss) on Plan Assets of $13.25 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Compensation Related Costs › Defined Benefit Plan
us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets · last filed 2026-03-13
- Onconetix, Inc. defined benefit plan, expected return (loss) on plan assets for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Onconetix, Inc. defined benefit plan, expected return (loss) on plan assets for the quarter ending 2025-09-30 was $2.26K.
- Onconetix, Inc. defined benefit plan, expected return (loss) on plan assets for the quarter ending 2025-06-30 was $5.70K.
- Onconetix, Inc. defined benefit plan, expected return (loss) on plan assets for the quarter ending 2025-03-31 was $5.29K, a 77.46% decline year-over-year.
- Onconetix, Inc. defined benefit plan, expected return (loss) on plan assets for fiscal 2025 was $13.25K, a 43.24% decline from fiscal 2024.
- Onconetix, Inc. defined benefit plan, expected return (loss) on plan assets for fiscal 2024 was $23.34K.
| Period end | Defined Benefit Plan, Expected Return (Loss) on Plan Assets 1 month | Defined Benefit Plan, Expected Return (Loss) on Plan Assets 3 month | Defined Benefit Plan, Expected Return (Loss) on Plan Assets 6 month | Defined Benefit Plan, Expected Return (Loss) on Plan Assets 9 month | Defined Benefit Plan, Expected Return (Loss) on Plan Assets 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $2.26K derived: sum of 2 quarters · filed 2026-03-13 | $7.96K derived: sum of 3 quarters · filed 2026-03-13 | $13.25K 10-K · filed 2026-03-13 | |
| 2025-09-30 | $2.26K 10-Q · filed 2025-11-13 | $7.96K derived: sum of 2 quarters · filed 2025-11-13 | $13.25K 10-Q · filed 2025-11-13 | $19.11K derived: sum of 4 quarters · filed 2026-03-13 | |
| 2025-06-30 | $5.70K 10-Q · filed 2025-08-14 | $10.99K 10-Q · filed 2025-08-14 | $16.85K derived: sum of 3 quarters · filed 2026-03-13 | $11.25K derived: sum of 4 quarters · filed 2026-03-13 | |
| 2025-03-31 | $5.29K derived: 10-K 12 month − 3 quarters · filed 2026-03-13 | $11.16K derived: sum of 2 quarters · filed 2026-03-13 | $5.55K derived: sum of 3 quarters · filed 2026-03-13 | $5.14K derived: sum of 4 quarters · filed 2026-03-13 | |
| 2024-12-31 | $5.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $257.00 derived: sum of 2 quarters · filed 2026-03-13 | -$152.00 derived: sum of 3 quarters · filed 2026-03-13 | $23.34K 10-K · filed 2026-03-13 | |
| 2024-09-30 | -$5.61K 10-Q · filed 2025-11-13 | -$6.01K derived: sum of 2 quarters · filed 2025-11-13 | $17.48K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | -$409.00 10-Q · filed 2025-08-14 | $23.09K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $23.50K 10-Q · filed 2024-05-20 | ||||
| 2023-12-31 | $1.58K 10-K · filed 2024-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |